CCN3 Antibody

• 产品编号：CST-8767S      品牌：CST       原厂货号：8767S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

CCN3 Antibody 识别内源性的CCN3总蛋白。该多克隆抗体由人CCN3蛋白118位精氨酸附近的短肽免疫动物产生。该抗体由protein A和肽亲和层析技术纯化。CCN3，也被命名为NOV(过度表达的肾母细胞瘤),属于CCN(Cyr61, Ctgf, NOV)家族蛋白。它是一种富含胱氨酸的分泌性蛋白，与细胞外基质组成部分有关联。同其他CCN家族成员一样，CCN3能够通过4种不同的结构域与很多蛋白配体结合从而介导多种生物学功能(1-5)。CCN3通过多种机制调节骨循环，并且它还参与诸如骨肉瘤、软骨肉瘤等初始骨癌的进展(6-8)。研究表明CCN3也参与黑色素瘤、乳腺癌及前列腺癌的骨代谢(9-11)。新近报道指出，CCN3在干细胞更新中起重要作用(12)。CCN3通常表达在胚胎和成人组织(13,14)。翻译后修饰及溶蛋白性裂解可以影响CCN3的活性(15,16)。

1. Perbal, B. (2001) Mol Pathol 54, 57-79.
2. Brigstock, D.R. et al. (2003) Mol Pathol 56, 127-8.
3. Leask, A. and Abraham, D.J. (2006) J Cell Sci 119, 4803-10.
4. Yeger, H. and Perbal, B. (2007) J Cell Commun Signal 1, 159-64.
5. McCallum, L. and Irvine, A.E. (2009) Blood Rev 23, 79-85.
6. Perbal, B. et al. (2008) Clin Cancer Res 14, 701-9.
7. Tzeng, H.E. et al. (2011) J Cell Physiol 226, 3181-9.
8. Yang, W. et al. (2011) Hum Reprod 26, 2850-60.
9. Vallacchi, V. et al. (2008) Cancer Res 68, 715-23.
10. Ouellet, V. et al. (2011) Am J Pathol 178, 2377-88.
11. Chen, P.C. et al. (2012) Carcinogenesis 33, 937-45.
12. Gupta, R. et al. (2007) Science 316, 590-3.
13. Burren, C.P. et al. (1999) J Clin Endocrinol Metab 84, 1096-103.
14. Kocialkowski, S. et al. (2001) Anat Embryol (Berl) 203, 417-27.
15. Perbal, B. et al. (1999) Proc Natl Acad Sci U S A 96, 869-74.
16. Su, B.Y. et al. (2001) Mol Pathol 54, 184-91.

原厂资料：

Specificity / Sensitivity

CCN3 Antibody recognizes endogenous levels of total CCN3 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg118 of human CCN3 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

CCN3, also named NOV (Nephroblastoma overexressed), belongs to the CCN (Cyr61, Ctgf, NOV) family of proteins. It is a cystine-rich secretory protein that associates with components of the extracellular matrix. Like other CCN family members, CCN3 is capable of mediating diverse biological functions through its four distinct domains, which enable binding to numerous protein partners (1-5). 
 
 CCN3 modulates bone turnover through various mechanisms and is implicated in the progression of primary bone cancers such as osteosarcoma and chondrosarcoma (6-8). Research has shown that CCN3 is also involved in the bone metastasis of melanoma, breast cancer, and prostate cancers (9-11). Recently, CCN3 was reported to play an important role in stem cell renewal (12). CCN3 is normally expressed in both embryonic and adult tissues (13,14). The activity of CCN3 is influenced by post translational modifications and proteolytic cleavage (15,16).

1. Perbal, B. (2001) Mol Pathol 54, 57-79.
2. Brigstock, D.R. et al. (2003) Mol Pathol 56, 127-8.
3. Leask, A. and Abraham, D.J. (2006) J Cell Sci 119, 4803-10.
4. Yeger, H. and Perbal, B. (2007) J Cell Commun Signal 1, 159-64.
5. McCallum, L. and Irvine, A.E. (2009) Blood Rev 23, 79-85.
6. Perbal, B. et al. (2008) Clin Cancer Res 14, 701-9.
7. Tzeng, H.E. et al. (2011) J Cell Physiol 226, 3181-9.
8. Yang, W. et al. (2011) Hum Reprod 26, 2850-60.
9. Vallacchi, V. et al. (2008) Cancer Res 68, 715-23.
10. Ouellet, V. et al. (2011) Am J Pathol 178, 2377-88.
11. Chen, P.C. et al. (2012) Carcinogenesis 33, 937-45.
12. Gupta, R. et al. (2007) Science 316, 590-3.
13. Burren, C.P. et al. (1999) J Clin Endocrinol Metab 84, 1096-103.
14. Kocialkowski, S. et al. (2001) Anat Embryol (Berl) 203, 417-27.
15. Perbal, B. et al. (1999) Proc Natl Acad Sci U S A 96, 869-74.
16. Su, B.Y. et al. (2001) Mol Pathol 54, 184-91.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibody.